 | • レポートコード：MRC2Q12-19071 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、一般抗がん注射剤のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 一般抗がん注射剤のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 一般抗がん注射剤の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 一般抗がん注射剤のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの一般抗がん注射剤の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の一般抗がん注射剤の売上および2028年までの予測に焦点を当てています。 一般抗がん注射剤のグローバル主要企業には、Teva、Viatris、Biocon、Amgen、Sandoz (Novartis)、Pfizer、Qilu Pharmaceutical、Jiangsu Hansoh、CTTQ、Jiangsu Hengrui、CSPC、Innovent Biologicsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 一般抗がん注射剤市場は、タイプとアプリケーションによって区分されます。世界の一般抗がん注射剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 ベバシズマブ、リツキシマブ、ハーセプチン、パクリタキセル、その他 【アプリケーション別セグメント】 病院、小売 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 一般抗がん注射剤製品概要 - タイプ別市場（ベバシズマブ、リツキシマブ、ハーセプチン、パクリタキセル、その他） - アプリケーション別市場（病院、小売） - 調査の目的 ・エグゼクティブサマリー - 世界の一般抗がん注射剤販売量予測2017-2028 - 世界の一般抗がん注射剤売上予測2017-2028 - 一般抗がん注射剤の地域別販売量 - 一般抗がん注射剤の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別一般抗がん注射剤販売量 - 主要メーカー別一般抗がん注射剤売上 - 主要メーカー別一般抗がん注射剤価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（ベバシズマブ、リツキシマブ、ハーセプチン、パクリタキセル、その他） - 一般抗がん注射剤のタイプ別販売量 - 一般抗がん注射剤のタイプ別売上 - 一般抗がん注射剤のタイプ別価格 ・アプリケーション別市場規模（病院、小売） - 一般抗がん注射剤のアプリケーション別販売量 - 一般抗がん注射剤のアプリケーション別売上 - 一般抗がん注射剤のアプリケーション別価格 ・北米市場 - 北米の一般抗がん注射剤市場規模（タイプ別、アプリケーション別） - 主要国別の一般抗がん注射剤市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの一般抗がん注射剤市場規模（タイプ別、アプリケーション別） - 主要国別の一般抗がん注射剤市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の一般抗がん注射剤市場規模（タイプ別、アプリケーション別） - 主要国別の一般抗がん注射剤市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の一般抗がん注射剤市場規模（タイプ別、アプリケーション別） - 主要国別の一般抗がん注射剤市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの一般抗がん注射剤市場規模（タイプ別、アプリケーション別） - 主要国別の一般抗がん注射剤市場規模（トルコ、サウジアラビア） ・企業情報 Teva、Viatris、Biocon、Amgen、Sandoz (Novartis)、Pfizer、Qilu Pharmaceutical、Jiangsu Hansoh、CTTQ、Jiangsu Hengrui、CSPC、Innovent Biologics ・産業チェーン及び販売チャネル分析 - 一般抗がん注射剤の産業チェーン分析 - 一般抗がん注射剤の原材料 - 一般抗がん注射剤の生産プロセス - 一般抗がん注射剤の販売及びマーケティング - 一般抗がん注射剤の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 一般抗がん注射剤の産業動向 - 一般抗がん注射剤のマーケットドライバー - 一般抗がん注射剤の課題 - 一般抗がん注射剤の阻害要因 ・主な調査結果 |
Market Analysis and Insights: Global Generic Anti-cancer Injectables Market
The global Generic Anti-cancer Injectables market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Bevacizuma accounting for % of the Generic Anti-cancer Injectables global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Generic Anti-cancer Injectables market size is valued at US$ million in 2021, while the North America and Europe Generic Anti-cancer Injectables are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Generic Anti-cancer Injectables landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Generic Anti-cancer Injectables market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Generic Anti-cancer Injectables market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Generic Anti-cancer Injectables market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Generic Anti-cancer Injectables market.
Global Generic Anti-cancer Injectables Scope and Market Size
Generic Anti-cancer Injectables market is segmented by players, region (country), by Type and by Channel. Players, stakeholders, and other participants in the global Generic Anti-cancer Injectables market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Channel for the period 2017-2028.
Segment by Type
Bevacizuma
Rituximab
Herceptin
Paclitaxel
Others
Segment by Channel
Hospital
Retail
By Company
Teva
Viatris
Biocon
Amgen
Sandoz (Novartis)
Pfizer
Qilu Pharmaceutical
Jiangsu Hansoh
CTTQ
Jiangsu Hengrui
CSPC
Innovent Biologics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Generic Anti-cancer Injectables Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Bevacizuma
1.2.3 Rituximab
1.2.4 Herceptin
1.2.5 Paclitaxel
1.2.6 Others
1.3 Market by Channel
1.3.1 Global Generic Anti-cancer Injectables Market Size Growth Rate by Channel, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Retail
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Generic Anti-cancer Injectables Market Perspective (2017-2028)
2.2 Generic Anti-cancer Injectables Growth Trends by Region
2.2.1 Generic Anti-cancer Injectables Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Generic Anti-cancer Injectables Historic Market Size by Region (2017-2022)
2.2.3 Generic Anti-cancer Injectables Forecasted Market Size by Region (2023-2028)
2.3 Generic Anti-cancer Injectables Market Dynamics
2.3.1 Generic Anti-cancer Injectables Industry Trends
2.3.2 Generic Anti-cancer Injectables Market Drivers
2.3.3 Generic Anti-cancer Injectables Market Challenges
2.3.4 Generic Anti-cancer Injectables Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Generic Anti-cancer Injectables Players by Revenue
3.1.1 Global Top Generic Anti-cancer Injectables Players by Revenue (2017-2022)
3.1.2 Global Generic Anti-cancer Injectables Revenue Market Share by Players (2017-2022)
3.2 Global Generic Anti-cancer Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Generic Anti-cancer Injectables Revenue
3.4 Global Generic Anti-cancer Injectables Market Concentration Ratio
3.4.1 Global Generic Anti-cancer Injectables Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Generic Anti-cancer Injectables Revenue in 2021
3.5 Generic Anti-cancer Injectables Key Players Head office and Area Served
3.6 Key Players Generic Anti-cancer Injectables Product Solution and Service
3.7 Date of Enter into Generic Anti-cancer Injectables Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Generic Anti-cancer Injectables Breakdown Data by Type
4.1 Global Generic Anti-cancer Injectables Historic Market Size by Type (2017-2022)
4.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Type (2023-2028)
5 Generic Anti-cancer Injectables Breakdown Data by Channel
5.1 Global Generic Anti-cancer Injectables Historic Market Size by Channel (2017-2022)
5.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Channel (2023-2028)
6 North America
6.1 North America Generic Anti-cancer Injectables Market Size (2017-2028)
6.2 North America Generic Anti-cancer Injectables Market Size by Type
6.2.1 North America Generic Anti-cancer Injectables Market Size by Type (2017-2022)
6.2.2 North America Generic Anti-cancer Injectables Market Size by Type (2023-2028)
6.2.3 North America Generic Anti-cancer Injectables Market Share by Type (2017-2028)
6.3 North America Generic Anti-cancer Injectables Market Size by Channel
6.3.1 North America Generic Anti-cancer Injectables Market Size by Channel (2017-2022)
6.3.2 North America Generic Anti-cancer Injectables Market Size by Channel (2023-2028)
6.3.3 North America Generic Anti-cancer Injectables Market Share by Channel (2017-2028)
6.4 North America Generic Anti-cancer Injectables Market Size by Country
6.4.1 North America Generic Anti-cancer Injectables Market Size by Country (2017-2022)
6.4.2 North America Generic Anti-cancer Injectables Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Generic Anti-cancer Injectables Market Size (2017-2028)
7.2 Europe Generic Anti-cancer Injectables Market Size by Type
7.2.1 Europe Generic Anti-cancer Injectables Market Size by Type (2017-2022)
7.2.2 Europe Generic Anti-cancer Injectables Market Size by Type (2023-2028)
7.2.3 Europe Generic Anti-cancer Injectables Market Share by Type (2017-2028)
7.3 Europe Generic Anti-cancer Injectables Market Size by Channel
7.3.1 Europe Generic Anti-cancer Injectables Market Size by Channel (2017-2022)
7.3.2 Europe Generic Anti-cancer Injectables Market Size by Channel (2023-2028)
7.3.3 Europe Generic Anti-cancer Injectables Market Share by Channel (2017-2028)
7.4 Europe Generic Anti-cancer Injectables Market Size by Country
7.4.1 Europe Generic Anti-cancer Injectables Market Size by Country (2017-2022)
7.4.2 Europe Generic Anti-cancer Injectables Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Generic Anti-cancer Injectables Market Size (2017-2028)
8.2 Asia-Pacific Generic Anti-cancer Injectables Market Size by Type
8.2.1 Asia-Pacific Generic Anti-cancer Injectables Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Generic Anti-cancer Injectables Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Generic Anti-cancer Injectables Market Share by Type (2017-2028)
8.3 Asia-Pacific Generic Anti-cancer Injectables Market Size by Channel
8.3.1 Asia-Pacific Generic Anti-cancer Injectables Market Size by Channel (2017-2022)
8.3.2 Asia-Pacific Generic Anti-cancer Injectables Market Size by Channel (2023-2028)
8.3.3 Asia-Pacific Generic Anti-cancer Injectables Market Share by Channel (2017-2028)
8.4 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region
8.4.1 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Generic Anti-cancer Injectables Market Size (2017-2028)
9.2 Latin America Generic Anti-cancer Injectables Market Size by Type
9.2.1 Latin America Generic Anti-cancer Injectables Market Size by Type (2017-2022)
9.2.2 Latin America Generic Anti-cancer Injectables Market Size by Type (2023-2028)
9.2.3 Latin America Generic Anti-cancer Injectables Market Share by Type (2017-2028)
9.3 Latin America Generic Anti-cancer Injectables Market Size by Channel
9.3.1 Latin America Generic Anti-cancer Injectables Market Size by Channel (2017-2022)
9.3.2 Latin America Generic Anti-cancer Injectables Market Size by Channel (2023-2028)
9.3.3 Latin America Generic Anti-cancer Injectables Market Share by Channel (2017-2028)
9.4 Latin America Generic Anti-cancer Injectables Market Size by Country
9.4.1 Latin America Generic Anti-cancer Injectables Market Size by Country (2017-2022)
9.4.2 Latin America Generic Anti-cancer Injectables Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Generic Anti-cancer Injectables Market Size (2017-2028)
10.2 Middle East & Africa Generic Anti-cancer Injectables Market Size by Type
10.2.1 Middle East & Africa Generic Anti-cancer Injectables Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Generic Anti-cancer Injectables Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Generic Anti-cancer Injectables Market Share by Type (2017-2028)
10.3 Middle East & Africa Generic Anti-cancer Injectables Market Size by Channel
10.3.1 Middle East & Africa Generic Anti-cancer Injectables Market Size by Channel (2017-2022)
10.3.2 Middle East & Africa Generic Anti-cancer Injectables Market Size by Channel (2023-2028)
10.3.3 Middle East & Africa Generic Anti-cancer Injectables Market Share by Channel (2017-2028)
10.4 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country
10.4.1 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Details
11.1.2 Teva Business Overview
11.1.3 Teva Generic Anti-cancer Injectables Introduction
11.1.4 Teva Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.1.5 Teva Recent Developments
11.2 Viatris
11.2.1 Viatris Company Details
11.2.2 Viatris Business Overview
11.2.3 Viatris Generic Anti-cancer Injectables Introduction
11.2.4 Viatris Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.2.5 Viatris Recent Developments
11.3 Biocon
11.3.1 Biocon Company Details
11.3.2 Biocon Business Overview
11.3.3 Biocon Generic Anti-cancer Injectables Introduction
11.3.4 Biocon Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.3.5 Biocon Recent Developments
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Amgen Business Overview
11.4.3 Amgen Generic Anti-cancer Injectables Introduction
11.4.4 Amgen Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.4.5 Amgen Recent Developments
11.5 Sandoz (Novartis)
11.5.1 Sandoz (Novartis) Company Details
11.5.2 Sandoz (Novartis) Business Overview
11.5.3 Sandoz (Novartis) Generic Anti-cancer Injectables Introduction
11.5.4 Sandoz (Novartis) Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.5.5 Sandoz (Novartis) Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Generic Anti-cancer Injectables Introduction
11.6.4 Pfizer Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.6.5 Pfizer Recent Developments
11.7 Qilu Pharmaceutical
11.7.1 Qilu Pharmaceutical Company Details
11.7.2 Qilu Pharmaceutical Business Overview
11.7.3 Qilu Pharmaceutical Generic Anti-cancer Injectables Introduction
11.7.4 Qilu Pharmaceutical Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.7.5 Qilu Pharmaceutical Recent Developments
11.8 Jiangsu Hansoh
11.8.1 Jiangsu Hansoh Company Details
11.8.2 Jiangsu Hansoh Business Overview
11.8.3 Jiangsu Hansoh Generic Anti-cancer Injectables Introduction
11.8.4 Jiangsu Hansoh Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.8.5 Jiangsu Hansoh Recent Developments
11.9 CTTQ
11.9.1 CTTQ Company Details
11.9.2 CTTQ Business Overview
11.9.3 CTTQ Generic Anti-cancer Injectables Introduction
11.9.4 CTTQ Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.9.5 CTTQ Recent Developments
11.10 Jiangsu Hengrui
11.10.1 Jiangsu Hengrui Company Details
11.10.2 Jiangsu Hengrui Business Overview
11.10.3 Jiangsu Hengrui Generic Anti-cancer Injectables Introduction
11.10.4 Jiangsu Hengrui Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.10.5 Jiangsu Hengrui Recent Developments
11.11 CSPC
11.11.1 CSPC Company Details
11.11.2 CSPC Business Overview
11.11.3 CSPC Generic Anti-cancer Injectables Introduction
11.11.4 CSPC Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.11.5 CSPC Recent Developments
11.12 Innovent Biologics
11.12.1 Innovent Biologics Company Details
11.12.2 Innovent Biologics Business Overview
11.12.3 Innovent Biologics Generic Anti-cancer Injectables Introduction
11.12.4 Innovent Biologics Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.12.5 Innovent Biologics Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer